Orphan status in Europe for Archemix TTP candidate
USA-based Archemix, a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics for rare hematological diseases, has received orphan drug designation for ARC1779 from the European Commission for the treatment of thrombotic thrombocytopenic purpura.
ARC1779 is currently in a Phase II trial designed to assess the safety, pharmacokinetics and pharmacodynamic effects of the drug candidate in approximately 28 patients with von Willebrand Factor-mediated platelet function disorders. Archemix expects this trial to conclude in the third quarter of 2008.
There is no drug currently approved for the treatment of TTP and acute episodes of the disease are associated with a significant mortality rate, estimated to be as high as 20%, says the firm. ARC1779 also received orphan drug designation from the US Food and Drug Administration in April.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze